JW THERAP-B2126.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, JW THERAP-B (2126.HK) trades at a negative P/E (-2.85x, due to a recent net loss), P/B of 2.09x, P/S of 3.33x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 87th percentile over the trailing 10Y window (vs. 96th percentile over 3Y); P/S sits at the 24th percentile over the trailing 10Y window (vs. 34th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 34th percentile within its industry and the 74th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. JW THERAP-B operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2126 · SEHK: 2126 · 2126
Want the full picture on whether JW THERAP-B (2126.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -2.85 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 2.09 | ||||||
| P/S (TTM) | 3.33 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |